ITGR

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 29, 2002, for Wilson Greatbatch Technologies, Inc. (Note: The request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.). The Company is a leading developer and manufacturer of power sources, feedthroughs, and wet tantalum capacitors for implantable medical devices, as well as commercial power sources for aerospace and oil/gas exploration. The Company operates two reportable segments: Medical and Commercial Power Sources.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 23% year-over-year. The Medical segment drove this growth with a 34% increase, fueled by demand for implantable cardioverter defibrillator (ICD) batteries and the inclusion of Greatbatch-Sierra revenues. Conversely, the Commercial segment declined 14% due to reduced oil and gas exploration activity.
• Profitability: Net income improved significantly from a loss of $75,000 in Q1 2001 to $3.3 million in Q1 2002. This turnaround is primarily attributed to the absence of a $3.0 million extraordinary loss on debt retirement that occurred in Q1 2001.
• Margin Compression: Gross margin decreased from 47% to 44%. Management attributed this to reduced royalty revenues, restructuring charges at Greatbatch-Sierra, and a product mix shift toward lower-margin capacitor and Greatbatch-Sierra products.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 50% to $5.7 million, driven by the inclusion of Greatbatch-Sierra costs, Six Sigma initiatives, and patent activity. R&D expenses increased 15% to $3.7 million.
• Accounting Changes: The adoption of SFAS No. 142 eliminated goodwill amortization effective December 29, 2001. Intangible amortization expense dropped from $1.6 million in Q1 2001 to $0.9 million in Q1 2002.

Guidance, Outlook, and Risks

• Liquidity and Capital: The Company maintains a solid balance sheet with $37.6 million in cash. Management expects cash from operations to meet working capital needs and planned capital expenditures, which are expected to increase in 2002 for production capacity and R&D facility expansion.
• Debt Structure: Total interest-bearing debt represents 27% of total capitalization. The Company has a $100 million credit facility (consisting of an $80 million term loan and $20 million revolving line) maturing in July 2006. As of March 29, 2002, $71.0 million was outstanding on the term loan, with no borrowings on the revolving line.
• Outlook: Management expects to maintain R&D spending at a minimum of 10% of revenues to support new technologies. The Company is in compliance with all financial covenants.
• Risks: Key risks include dependence on a limited number of customers, product obsolescence, pricing pressure, reliance on third-party suppliers, and regulatory changes in the healthcare industry. Market risk exists regarding interest rate fluctuations on variable-rate debt.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 34% growth in the Medical segment, specifically the demand for ICD batteries and the integration of Greatbatch-Sierra.
• Margin Trends: Monitor whether the 3-percentage-point decline in gross margin is a one-time effect of product mix and restructuring or a structural shift.
• Debt Covenants: Confirm continued compliance with EBITDA and leverage ratios required by the $100 million credit facility.
• Capital Expenditures: Track the execution of planned capital expenditures for R&D facility expansion and production capacity increases.
• Customer Concentration: Assess the impact of the Company's dependence on a limited number of customers, particularly in the medical device sector.